MREO SEC Filings: 8-K, 10-Q, S-3 & 424B – Mereo BioPharma

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 12, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 19, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 10, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 12, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWMereo BioPharma Reports Third Quarter 2026 Financial Results and Provides Pipeline Updates

Nov 9, 2026

8-K

Mereo BioPharma Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Aug 19, 2026

8-K

Mereo BioPharma Reports Q2 2026 Financial Results and Alvelestat Licensing Agreement

Aug 11, 2026

8-K

Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for Alvelestat

Aug 11, 2026

8-K

Mereo BioPharma Group plc Announces Results of 2026 Annual General Meeting

May 14, 2026

8-K/A

Mereo BioPharma Reports First Quarter 2026 Financial Results and Corporate Updates

May 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 2, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 23, 2025

S-3

SHELF EFFECTIVE

Nov 25, 2024

S-3

SHELF | ATM | Offering amount: $175,000,000.00 EFFECTIVE

May 15, 2024

S-8

Registration

Jan 23, 2024

8-A12B/A

Registration

Dec 18, 2023

Proxies

TYPE

HEADLINE

FILED AT

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 9, 2026

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 27, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 8, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 24, 2024

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

BANK OF AMERICA CORP /DE/ (Filed by)

Oct 28, 2026

SCHEDULE 13G/A

EcoR1 Capital, LLC (Filed by)

Aug 14, 2026

SCHEDULE 13G/A

EcoR1 Capital, LLC (Filed by)

May 15, 2026

SCHEDULE 13G

BANK OF AMERICA CORP /DE/ (Filed by)

May 14, 2026

Jacquet Pierre (Reporting)

Feb 27, 2026

Yoskowitz Marc J (Reporting)

Feb 27, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 5, 2024

CORRESP

Form CORRESP - Correspondence

Dec 3, 2024

LETTER

Form UPLOAD - SEC-generated letter

Dec 2, 2024

EFFECT

Form EFFECT - Notice of Effectiveness

May 28, 2024

CORRESP

Form CORRESP - Correspondence

May 21, 2024

LETTER

Form UPLOAD - SEC-generated letter

May 20, 2024

Mereo BioPharma Group plc MREO · SEC Filings